NCT00995930View on ClinicalTrials.gov

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Diabetes Mellitus, Type 2AtherosclerosisPrediabetic State
Interventions
DRUG

ACZ885

ACZ885 150 mg was administered subcutaneously once a month for 12 months.

DRUG

Placebo

Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.

Trial Locations (9)

10029

Novartis Investigative Site, New York

41460

Novartis Investigative Site, Neuss

45219

Novartis Investigative Site, Cincinnati

55116

Novartis Investigative Site, Mainz

89081

Novartis Investigative Site, Ulm

91120

Novartis Investigative Site, Jerusalem

H1T 1C8

Novartis Investigative Site, Montreal

OX2 6HE

Novartis Investigative Site, Oxford

EC1M 6BQ

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY